Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.

Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 2013 May 10; 31(14):1726-31.

View in: PubMed

subject areas

Adult
Aged
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Hormonal
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Drug Administration Schedule
Female
Humans
Lymphatic Metastasis
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Nitriles
Quinazolines
Receptor, ErbB-2
Receptors, Estrogen
Trastuzumab
Treatment Outcome
Triazoles
Up-Regulation

authors with profiles

Rita Nanda